Novo Nordisk A/S
Every calculator, already run for NVO
Open the full toolkit →You have the numbers on NVO. Get the argument.
A written report on which of these readings actually decide the outcome for Novo Nordisk A/S, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering NVOAnalyst Price Target Disagreement for Novo Nordisk A/S
Wall Street's bull case implies +47% from the current price; the bear case implies -8%. A 56% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for NVO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-…
NVO — frequently asked
Is NVO a buy right now?
Wall Street's consensus rating on Novo Nordisk A/S is Hold across 14 analysts, with a mean price target of $47.00 (+9% vs. the current $43.24). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is NVO overvalued?
NVO trades at 10.6x trailing earnings, against a DCF fair value of $438 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is NVO's next earnings date?
Novo Nordisk A/S is next scheduled to report earnings around Nov 4, 2026. A full NVO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Novo Nordisk A/S?
Analysts covering Novo Nordisk A/S (NVO) range from a bear-case target of $39.72 to a bull-case high of $63.72, with a mean consensus target of $47.00 across 12 analysts. The spread of $24.00 (56% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Novo Nordisk A/S against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Novo Nordisk A/S
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full NVO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Novo Nordisk A/S, in minutes. 3 free reports included with every account — no credit card required.